‘Bond market tantrum risks’: Gilt traders brace for Labour leftward pivot as Starmer future uncertain
Froth and love in a wonderful, light romance May 14, 2009 TheatreDUET FOR ONEVaudeville TheatreDUET for One provides us with what must be one of the West End’s most poignant performances in recent times, in the shape of Juliet Stevenson’s musician whose career has been curtailed by multiple sclerosis. It is a masterclass in control, nuance and subtle physicality, without ever seeming anything other than entirely [...]
A CONSERVATORY IS THE BEST WAY TO ENJOY THE SUMMER May 14, 2009 WITH a rare hot summer on the way, making use of your outdoor space this year will be a priority for anyone with a garden and a bit of an itch to renovate. Enter the conservatory. Banish thoughts of hyacinth-filled, musty rooms belonging to ladies with cats or ageing parents. They are an increasingly sleek [...]
Mykonos calls for it-boy who gave it all up July 4, 2008 He failed to buy the Groucho, but Benjamin Fry has no regrets, writes Timothy Barber Benjamin Fry, psychotherapist, TV self-help guru and author, has come a long way. He used to be Benji Fry, stalwart of a west London scene of ultra connected upstarts such as Tom Parker Bowles and Ben Elliot, who in the [...]
Relief at CAT Abbott deal October 27, 2005 Cambridge Antibody Technology (CAT) has reached an agreement with American pharmaceutical firm Abbott about how much it should get in royalties from the sale of the blockbuster arthritis drug Humira. The deal, which sent shares in the loss-making British biopharmaceutical company up almost 4 per cent, has headed off a Court of Appeal’s case scheduled [...]
The new drug habits October 21, 2005 Pharmaceutical companies are increasingly turning to biotechnology ventures to help them rescue their flagging profits. Investors are looking at biotechnology companies to reinvigorate a moribund drug industry in a way the big pharmaceutical giants have failed to do over the last two years. Observers say companies such as America’s Pfizer or Britain’s GlaxoSmithKline, known as [...]